Background: Palliative care improves symptoms and coping in patients with advanced cancers, but has not been evaluated for patients with curable solid malignancies. Because of the tremendous symptom burden and high rates of psychological distress in head and neck cancer (HNC), we evaluated feasibility and acceptability of a palliative care intervention in patients with HNC receiving curative-intent chemoradiation therapy (CRT). Methods: This was a prospective single-arm study in HNC patients receiving CRT at a single center in the United States. The intervention entailed weekly palliative care visits integrated with oncology care with a focus on symptoms and coping. The primary outcome was feasibility, defined as a >50% enrollment rate with >70% of patients attending at least half of the visits. To assess acceptability, we collected satisfaction ratings post-intervention. We also explored symptom burden, mood, and quality of life (QOL). Results: We enrolled 91% (20/22) of eligible patients. Patients attended 133 of 138 palliative care visits (96%); all 20 attended >85% of visits. Eighteen of 19 (95%) found the intervention "very helpful" and would "definitely recommend" it. QOL and symptom burden worsened from baseline to week 5, but subsequently improved at one-month post-CRT. Overall, patients valued the one-on-one format of the intervention and receipt of additional care. Conclusions: Our palliative care intervention during highly morbid CRT was feasible and acceptable with high enrollment, excellent intervention compliance, and high patient satisfaction. Future randomized studies will further explore the impact on patient-reported outcomes and health care utilization.
Background: Palliative care improves symptoms and coping in patients with advanced cancers, but has not been evaluated for patients with curable solid malignancies. Because of the tremendous symptom burden and high rates of psychological distress in head and neck cancer (HNC), we evaluated feasibility and acceptability of a palliative care intervention in patients with HNC receiving curative-intent chemoradiation therapy (CRT). Methods: This was a prospective single-arm study in HNC patients receiving CRT at a single center in the United States. The intervention entailed weekly palliative care visits integrated with oncology care with a focus on symptoms and coping. The primary outcome was feasibility, defined as a >50% enrollment rate with >70% of patients attending at least half of the visits. To assess acceptability, we collected satisfaction ratings post-intervention. We also explored symptom burden, mood, and quality of life (QOL). Results: We enrolled 91% (20/22) of eligible patients. Patients attended 133 of 138 palliative care visits (96%); all 20 attended >85% of visits. Eighteen of 19 (95%) found the intervention "very helpful" and would "definitely recommend" it. QOL and symptom burden worsened from baseline to week 5, but subsequently improved at one-month post-CRT. Overall, patients valued the one-on-one format of the intervention and receipt of additional care. Conclusions: Our palliative care intervention during highly morbid CRT was feasible and acceptable with high enrollment, excellent intervention compliance, and high patient satisfaction. Future randomized studies will further explore the impact on patient-reported outcomes and health care utilization.
Entities:
Keywords:
chemoradiation therapy; head and neck cancer; palliative care; supportive care
Authors: K Aro; L Bäck; V Loimu; K Saarilahti; S Rogers; H Sintonen; R Roine; Antti Mäkitie Journal: Eur Arch Otorhinolaryngol Date: 2015-07-28 Impact factor: 2.503
Authors: Joseph A Greer; Jamie M Jacobs; Areej El-Jawahri; Ryan D Nipp; Emily R Gallagher; William F Pirl; Elyse R Park; Alona Muzikansky; Juliet C Jacobsen; Vicki A Jackson; Jennifer S Temel Journal: J Clin Oncol Date: 2017-11-15 Impact factor: 44.544
Authors: A Pollard; J L Burchell; D Castle; K Neilson; M Ftanou; J Corry; D Rischin; D W Kissane; M Krishnasamy; L E Carlson; J Couper Journal: Eur J Cancer Care (Engl) Date: 2016-03-07 Impact factor: 2.520
Authors: A M H Krebber; F Jansen; B I Witte; P Cuijpers; R de Bree; A Becker-Commissaris; E F Smit; A van Straten; A M Eeckhout; A T F Beekman; C R Leemans; I M Verdonck-de Leeuw Journal: Ann Oncol Date: 2016-06-10 Impact factor: 32.976
Authors: Lauren C Capozzi; Margaret L McNeely; Harold Y Lau; Raylene A Reimer; Janine Giese-Davis; Tak S Fung; S Nicole Culos-Reed Journal: Cancer Date: 2016-02-01 Impact factor: 6.860